News Merus N.V.

Equities

MRUS

NL0011606264

Market Closed - Nasdaq Other stock markets 03:59:47 2024-06-04 pm EDT			5-day change	1st Jan Change
50.37 ^USD	-4.85%		-8.20%	+83.16%

Jun. 04	BMO Capital Raises Price Target on Merus to $91 From $84, Maintains Outperform Rating	MT
Jun. 04	Canaccord Genuity Adjusts Price Target on Merus to $67 From $54, Maintains Buy Rating	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BMO Capital Raises Price Target on Merus to $91 From $84, Maintains Outperform Rating	Jun. 04	MT
Canaccord Genuity Adjusts Price Target on Merus to $67 From $54, Maintains Buy Rating	Jun. 04	MT
Merus Says Target Tumors in Lung Cancer Patients Decrease in Size After MCLA-129 Treatment	Jun. 03	MT
Merus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting	Jun. 03	GL
Truist Securities Raises Price Target on Merus to $88 From $69, Maintains Buy Rating	Jun. 03	MT
Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting	Jun. 02	AQ
Merus N.V. Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab At the 2024 ASCO® Annual Meeting	Jun. 02	CI
Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting	Jun. 02	GL
Merus Prices $400.2 Million Public Share Offering	May. 30	MT
Merus Announces Pricing of Upsized Public Offering of Common Shares	May. 29	GL
BofA Securities Adjusts Merus Price Target to $80 From $61, Maintains Buy Rating	May. 29	MT
Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference	May. 29	GL
Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference	May. 29	AQ
HC Wainwright Adjusts Price Target on Merus to $85 From $65, Maintains Buy Rating	May. 29	MT
Merus Launches $300 Million Stock Offering	May. 28	MT
Merus N.V. Announces Proposed Public Offering of Common Shares	May. 28	GL
Guggenheim Adjusts Merus Price Target to $93 From $57, Maintains Buy Rating	May. 28	MT
BMO Capital Adjusts Merus Price Target to $84 From $58, Maintains Outperform Rating	May. 28	MT
Stifel Adjusts Price Target on Merus to $90 From $65, Maintains Buy Rating	May. 28	MT
Merus’ Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC	May. 28	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Merus N.V.

Equities

MRUS

NL0011606264

Summary

Filters